Navigation Links
OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
Date:9/2/2008

BOTHELL, WA and VANCOUVER, Sept. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) ("OncoGenex" or the "Company") has announced today that it has granted to Eagle Pharmaceuticals, Inc. the exclusive worldwide rights to develop and commercialize TOCOSOL(R) Paclitaxel. Under the terms of the agreement, OncoGenex is entitled to receive royalty payments from future TOCOSOL Paclitaxel sales and a percentage of sub-licensing royalty and milestone payments received by Eagle Pharmaceuticals. All development expenses are the sole responsibility of Eagle Pharmaceuticals. No upfront payments or milestone payments were included in this transaction and no further terms have been disclosed.

TOCOSOL Paclitaxel was previously developed by Sonus Pharmaceuticals prior to the combination of Sonus and OncoGenex Technologies to form the Company on August 21, 2008. In previous disclosures, the Company stated that it had terminated further development of TOCOSOL Paclitaxel and would evaluate alternative strategies for the program, including out-licensing.

"We intend to focus all of our efforts on the deep pipeline we currently have in development, including OGX-011 which is completing five Phase 2 clinical studies in prostate, breast and lung cancers," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "TOCOSOL Paclitaxel was not part of that strategy, and we are pleased to be able to out-license the program to an organization with interest in continuing development of this product candidate."

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatme
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
2. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
3. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
6. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
7. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
8. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics including high value and difficult ... follow-on public offering of 6,000,000 shares of its common ... per share. Of the shares being offered, 2,610,000 are ... are being offered by existing stockholders. Pfenex will not ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of its ... lighting market. In recent months, there have ... emerging markets such as Russia, South America, and ... such as streetlight and area lighting, tunnel lighting, ... in 2005 the Acrich technology from Seoul Semiconductor ...
(Date:4/23/2015)... 23, 2015 /CNW/ - A new and innovative service ... North America,s largest packaging ... Silver in the "Sustainability, service" category of the ... "Competitor Comparison" is a service that scores clients, ... Global peers. This benchmarking process shows clients how ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... AUXL ) today announced that executive management will ... held June 4-7, 2012 at the Grand Hyatt in New ... is scheduled to present an overview of the Company and ... 4, 2012. A breakout session will be held following the ...
... PARSIPPANY, N.J., May 29, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... company, announced today that Paul Bisaro, Watson,s President and ... of the Company,s business at the Goldman Sachs Global ... 8:00AM Pacific Time at the Terranea Resort in Rancho ...
... conditions such as multiple sclerosis and heart and liver ... and life sciences facilities opened yesterday by HRH, the ... unveil plaques this afternoon at the $85 million Scottish ... facility, Nine, in Edinburgh. The University of ...
Cached Biology Technology:Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 2Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 3Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 4Watson to Present at Goldman Sachs Global Healthcare Conference 2012 2Scotland opens stem cell research center and bio-medical incubator 2
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Hackensack, NJ (June 29, 2011) Researchers at the John ... of social support to distress after stem cell transplants. Scott ... the John Theurer Cancer Center at Hackensack University Medical Center ... Labay from Mt. Sinai. The study was published in the ...
... CORPUS CHRISTI Just as corn and ... discovered multi-beneficial uses and applications, Texas AgriLife Research scientists ... "It,s a huge, untapped source of fuel, food, ... a crop physiologist at the Texas AgriLife Research and ...
... rebirth, but if it comes too early, it can threaten ... of Alberta study shows that climate change over the past ... and trees into earlier blooming times, making them more vulnerable ... of A PhD candidate Elisabeth Beaubien and her supervisor, professor ...
Cached Biology News:John Theurer Cancer Center BMT researchers highlight the importance of social support 2Microalgae could be Texas' next big cash crop 2Microalgae could be Texas' next big cash crop 3
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
EMBP (FL-222)...
... PhosphatidylEthanolamine-Binding Protein (PEBP) does not share ... inhibitors. PEBP is expressed in ... ovary, muscle, and stomach. One ... is exerting inhibitory activity against several ...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: